Rapport Therapeutics, Inc. (RAPP) key performance indicators and operating metrics (15 metrics) from SEC EDGAR filings, earnings calls, and investor decks. First-party data.
| Metric | Latest Value | Period |
|---|---|---|
| Patients Enrolled in RAP-219-FOS-201 | 30.00 | FY2026-Q2 |
| Median Reduction in Clinical Seizure Frequency | 77.80 percent | FY2025-Q4 |
| Patients Achieving at Least 50% Reduction in Clinical Seizures | 72.00 percent | FY2025-Q4 |
| Patients Achieving Clinical Seizure Freedom | 24.00 percent | FY2025-Q4 |
| RAP-219 Half-Life | 22.00 | FY2026-Q2 |
| Healthy Volunteers Exposed to RAP-219 | 100.00 | FY2025-Q2 |
| Treatment-Emergent Adverse Event-Related Treatment Discontinuations | 10.00 percent | FY2025-Q3 |
| Phase 1 Trials | 4.00 | FY2025-Q2 |
| Participants Exposed to RAP-219 in Multiple Ascending Dose Trials | 48.00 | FY2025-Q1 |
| Headache | 5.00 | FY2025-Q3 |
| Brain Fog | 5.00 | FY2025-Q2 |
| Dry Mouth | 5.00 | FY2025-Q2 |
| Fatigue | 4.00 | FY2025-Q3 |
| Participants Exposed to Placebo | 16.00 | FY2025-Q1 |
Back to RAPP overview · RAPP earnings · RAPP holders
Data sourced from U.S. SEC EDGAR filings, earnings call transcripts, and investor decks. Not personalized investment advice.